E-GEOD-19234 - Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.
Released on 30 November 2009, last updated on 27 March 2012
Although remission rates for metastatic melanoma are generally very poor, some patients can survive for prolonged periods following metastasis. We used gene expression profiling, mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions to search for a molecular basis for this observation and to develop improved methods for predicting patient survival. We identified a group of 266 genes associated with postrecurrence survival. Genes positively associated with survival were predominantly immune response related (e.g., ICOS, CD3d, ZAP70, TRAT1, TARP, GZMK, LCK, CD2, CXCL13, CCL19, CCR7, VCAM1) while genes negatively associated with survival were cell proliferation related (e.g., PDE4D, CDK2, GREF1, NUSAP1, SPC24). Identification of genes associated with survival of metastatic melanoma Survival Analysis was performed using Statistical Analysis of Microarrays B D denotes same patient with multiple reccurences
transcription profiling by array
Dusan Bogunovic <email@example.com>, Anna C Plavlick, Farbod Darvishian, Ilana Belitskaya-Levy, Iman Osman, Jiri Zavadil, Nina Bhardwaj, Richard Shapiro, Russell Berman, Stefano Lonardi
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, Lonardi S, Zavadil J, Osman I, Bhardwaj N. , Europe PMC 19915147